Day One nabs its first ADC from MabCare for $55M
上市批准抗体药物偶联物并购临床1期引进/卖出
Hot off its first FDA approval, Day One Biopharmaceuticals added a new early-stage programme to its oncology pipeline on Tuesday, hopping into the much-hyped antibody-drug conjugate (ADC) space. For more analysis on deals involving the modality, see Vital Signs: Tracking the new converts to ADCs.
The California-based biotech licensed ex-China rights to MTX-13, a PTK7-targeting ADC, from MabCare Therapeutics. Day One will rename the candidate DAY301 and plans to start a Phase I trial in solid tumours by the first quarter of 2025.
The Chinese firm will receive $55 million upfront and is eligible for up to $1.15 billion in development, regulatory and commercial milestones, plus low-to-mid single-digit royalties.
Solving PTK7
Day One is betting on a less-well-known target for its first ADC. According to the company, PTK7 is a catalytically inactive transmembrane protein that is overexpressed in multiple solid tumours and underexpressed in healthy tissues.
However, an ADC against the kinase has yet to find clinical success. AbbVie and Pfizer had been working together to develop a PTK7-targeting ADC, cofetuzumab pelidotin, but both pharmas binned the candidate last year.
Genmab may have the only PTK7-directed ADC in the clinic. The company gained PRO1107, which is in a Phase I/II study for solid tumours, when it agreed in April to buy out ProfoundBio for $1.8 billion in cash. For more, see ViewPoints: How ProfoundBio fits into Genmab’s growth strategy.
Samuel Blackman, Day One’s head of R&D, said that the company believes “the linker-payload technology embodied in DAY301 will overcome the limitations of earlier PTK7-targeted ADCs, giving us a potential first-in-class drug against a clinically-validated target.”
Wednesday’s deal gives Day One its fourth cancer programme. The FDA in April approved Day One’s pan-RAF kinase inhibitor Ojemda (tovorafenib) to treat relapsed or refractory low-grade glioma with an activating BRAF alteration. The company’s pipeline also includes MEK 1/2 inhibitorMEK 1/2 inhibitor pimasertib, which is in a Phase I/II trial for solid tumours with MAPK pathway aberrations, and a preclinical VRK1 inhibitor gained from Sprint Bio last year for a mere $3 million upfront.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
适应症
热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。